Edition:
India

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

29.36CHF
19 Jan 2018
Change (% chg)

CHF0.54 (+1.87%)
Prev Close
CHF28.82
Open
CHF28.86
Day's High
CHF29.84
Day's Low
CHF28.62
Volume
522,317
Avg. Vol
413,337
52-wk High
CHF29.84
52-wk Low
CHF10.00

Chart for

About

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including... (more)

Overall

Beta: --
Market Cap(Mil.): CHF2,096.57
Shares Outstanding(Mil.): 119.12
Dividend: --
Yield (%): --

Financials

Idorsia to get $230 million from J&J in latest hypertension deal

ZURICH Idorsia , the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) , will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

04 Dec 2017

Idorsia to get $230 mln from J&J in latest hypertension deal

ZURICH, Dec 4 Idorsia, the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J), will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

04 Dec 2017

BRIEF-Idorsia Announces Collaboration With Janssen Biotech On Aprocitentan

* IDORSIA ANNOUNCES COLLABORATION WITH JANSSEN BIOTECH ON APROCITENTAN (ACT-132577)

04 Dec 2017

BRIEF-Idorsia ‍H1 ‍US GAAP operating loss of CHF 11 million​

* ‍GUIDANCE FOR FULL YEAR 2017: NON-GAAP OPERATING EXPENSES OF CHF 180-190 MILLION​

03 Aug 2017

BRIEF-Idorsia: Act-541468 (Dora) meets primary endpoint in Phase 2

* ACT-541468 (DORA) MEETS PRIMARY ENDPOINT IN PHASE 2 PROGRAM IN ADULT AND ELDERLY PATIENTS WITH INSOMNIA

28 Jul 2017

Earnings vs. Estimates